Key result
Clenbuterol up to daily linked to STEMI from coronary thrombosis in a bodybuilder.
Case Report (n=1)
Clenbuterol use in young athletes can precipitate acute coronary syndrome via vasospasm and thrombosis even in the absence of traditional risk factors.
Answers are grounded in this paper and cite their sources.
Highlights severe thrombotic risk with illicit sympathomimetic use in young athletes; extends toxicological profiles.
A professional bodybuilder in his 20s presented to the cardiology emergency with acute, retrosternal chest pain and diaphoresis lasting 3 hours. He reported using clenbuterol, a sympathomimetic drug known for its anabolic and lipolytic effects, at escalating doses up to 180 µg daily. ECG revealed normal sinus rhythm with ST-segment elevation in the anterior leads with raised serum troponin levels. Coronary angiography identified a grade IV thrombus in the proximal left anterior descending artery with thrombolysis in myocardial infarction 3 flow and normal flow in the remaining vessels. The patient was treated medically with anticoagulation, antiplatelets and statins and discharged on dual antiplatelet therapy, statins and guideline-directed medical therapy. This case highlights the importance of considering clenbuterol-induced vasospasm and thrombosis as a precipitating factor for acute coronary syndrome in young patients without traditional risk factors.
No takes yet. Share an insight, caveat, or question.
Aggarwal et al. (2025) conducted a case report in Acute myocardial infarction (n=1). Clenbuterol was evaluated on Acute myocardial infarction. Clenbuterol use at escalating doses up to daily precipitated an acute ST-segment elevation myocardial infarction due to coronary thrombosis in a young bodybuilder.
Synapse has enriched 10 related papers. Consider them for comparative context: